CompletedNCT01185743
Antipsychotic Treatment and Gene Activity in Schizophrenia
About this title
Read the official source — NCT01185743Medication studyAges 18–45Austria
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- ViennaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- Medical University of Vienna
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Austria
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT01185743
- Official title
Show the full official title
Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vienna
Questions about this study
Who is behind this study?
The study sponsor is Medical University of Vienna, a university.
Did this study involve medication?
Yes. The study involved medication, including olanzapine, ziprasidone and placebo.
Who was this study for?
Listed age limits: 18 years to 45 years.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia.